We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Regeneron’s Arcalyst Gout Drug Gets July PDUFA Target
Regeneron’s Arcalyst Gout Drug Gets July PDUFA Target
December 2, 2011
The FDA has set a July 30, 2012, user fee action goal date to review Regeneron’s sBLA for interleukin-1 inhibitor Arcalyst to treat gout flare-ups.